Abby R Rosenberg1, Liliana Orellana2, Christina Ullrich3, Tammy Kang4, J Russell Geyer5, Chris Feudtner4, Veronica Dussel6, Joanne Wolfe7. 1. Seattle Children's Hospital Cancer and Blood Disorders Center, Seattle, Washington, USA; Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA; Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research Institute, Seattle, Washington, USA. 2. Biostatistics Unit, Faculty of Health, Deakin University, Geelong, Victoria, Australia. 3. Department of Psychosocial Oncology and Palliative Care, Boston, Massachusetts, USA; Center for Outcomes and Policy Research, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Medicine, Boston Children's Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA. 4. Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 5. Seattle Children's Hospital Cancer and Blood Disorders Center, Seattle, Washington, USA; Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 6. Department of Medicine, Boston Children's Hospital, Boston, Massachusetts, USA; Center for Research and Implementation in Palliative Care, Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina. 7. Department of Psychosocial Oncology and Palliative Care, Boston, Massachusetts, USA; Center for Outcomes and Policy Research, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Medicine, Boston Children's Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA. Electronic address: joanne_wolfe@dfci.harvard.edu.
Abstract
CONTEXT: Modifiable factors of health-related quality of life (HRQOL) are poorly described among children with advanced cancer. Symptom distress may be an important factor for intervention. OBJECTIVES: We aimed to describe patient-reported HRQOL and its relationship to symptom distress. METHODS: Prospective, longitudinal data from the multicenter Pediatric Quality of Life and Symptoms Technology study included primarily patient-reported symptom distress and HRQOL, measured at most weekly with the Memorial Symptoms Assessment Scale and Pediatric Quality of Life inventory, respectively. Associations were evaluated using linear mixed-effects models adjusting for sex, age, cancer type, intervention arm, treatment intensity, and time since disease progression. RESULTS: Of 104 enrolled patients, 49% were female, 89% were white, and median age was 12.6 years. Nine hundred and twenty surveys were completed over nine months of follow-up (84% by patients). The median total Pediatric Quality of Life score was 74 (interquartile range 63-87) and was "poor/fair" (e.g., <70) 38% of the time. "Poor/fair" categories were highest in physical (53%) and school (48%) compared to emotional (24%) and social (16%) subscores. Thirteen of 24 symptoms were independently associated with reductions in overall or domain-specific HRQOL. Patients commonly reported distress from two or more symptoms, corresponding to larger HRQOL score reductions. Neither cancer type, time since progression, treatment intensity, sex, nor age was associated with HRQOL scores in multivariable models. Among 25 children completing surveys during the last 12 weeks of life, 11 distressing symptoms were associated with reductions in HRQOL. CONCLUSION: Symptom distress is strongly associated with HRQOL. Future research should determine whether alleviating distressing symptoms improves HRQOL in children with advanced cancer.
CONTEXT: Modifiable factors of health-related quality of life (HRQOL) are poorly described among children with advanced cancer. Symptom distress may be an important factor for intervention. OBJECTIVES: We aimed to describe patient-reported HRQOL and its relationship to symptom distress. METHODS: Prospective, longitudinal data from the multicenter Pediatric Quality of Life and Symptoms Technology study included primarily patient-reported symptom distress and HRQOL, measured at most weekly with the Memorial Symptoms Assessment Scale and Pediatric Quality of Life inventory, respectively. Associations were evaluated using linear mixed-effects models adjusting for sex, age, cancer type, intervention arm, treatment intensity, and time since disease progression. RESULTS: Of 104 enrolled patients, 49% were female, 89% were white, and median age was 12.6 years. Nine hundred and twenty surveys were completed over nine months of follow-up (84% by patients). The median total Pediatric Quality of Life score was 74 (interquartile range 63-87) and was "poor/fair" (e.g., <70) 38% of the time. "Poor/fair" categories were highest in physical (53%) and school (48%) compared to emotional (24%) and social (16%) subscores. Thirteen of 24 symptoms were independently associated with reductions in overall or domain-specific HRQOL. Patients commonly reported distress from two or more symptoms, corresponding to larger HRQOL score reductions. Neither cancer type, time since progression, treatment intensity, sex, nor age was associated with HRQOL scores in multivariable models. Among 25 children completing surveys during the last 12 weeks of life, 11 distressing symptoms were associated with reductions in HRQOL. CONCLUSION: Symptom distress is strongly associated with HRQOL. Future research should determine whether alleviating distressing symptoms improves HRQOL in children with advanced cancer.
Authors: J Wolfe; H E Grier; N Klar; S B Levin; J M Ellenbogen; S Salem-Schatz; E J Emanuel; J C Weeks Journal: N Engl J Med Date: 2000-02-03 Impact factor: 91.245
Authors: Pamela S Hinds; Donna Drew; Linda L Oakes; Maryam Fouladi; Sheri L Spunt; Christopher Church; Wayne L Furman Journal: J Clin Oncol Date: 2005-09-19 Impact factor: 44.544
Authors: John J Collins; Tom D Devine; Gina S Dick; Elizabeth A Johnson; Henry A Kilham; C Ross Pinkerton; M M Stevens; Howard T Thaler; Russell K Portenoy Journal: J Pain Symptom Manage Date: 2002-01 Impact factor: 3.612
Authors: Maya F Ilowite; Hasan Al-Sayegh; Clement Ma; Veronica Dussel; Abby R Rosenberg; Chris Feudtner; Tammy I Kang; Joanne Wolfe; Kira Bona Journal: Cancer Date: 2018-09-14 Impact factor: 6.860
Authors: Meaghann S Weaver; Abby R Rosenberg; Julia Tager; Christopher S Wichman; Lori Wiener Journal: J Palliat Med Date: 2017-11-27 Impact factor: 2.947
Authors: Christina K Ullrich; Veronica Dussel; Liliana Orellana; Tammy I Kang; Abby R Rosenberg; Chris Feudtner; Joanne Wolfe Journal: Cancer Date: 2018-10-06 Impact factor: 6.860
Authors: Angela Steineck; Krysta S Barton; Miranda C Bradford; Joyce P Yi-Frazier; Abby R Rosenberg Journal: J Adolesc Young Adult Oncol Date: 2021-05-06 Impact factor: 2.223